Becker's Healthcare January 8, 2025
Johnson & Johnson released results from a phase 3 study, showing that the combination of Rybrevant and Lazcluze significantly improved overall survival in patients with advanced non-small cell lung cancer that has specific epidermal growth factor receptor mutations.
The study, which included 1,074 patients, found that the chemotherapy-free regimen outperformed the current standard care, osimertinib, in extending patient survival, according to a Jan. 7 news...
Today's Sponsors
Today's Sponsor